Involvement of brain pericyte damage in neuropathological changes associated with lysosomal storage

Zhou Wu
Kyushu University, Japan

Recent evidence suggests that peripheral blood mononuclear cells (PBMCs) contribute to the pathogenesis of neuropathological changes in patients with neuronal ceroid-lipofuscinosis (NCL) and lysosomal storage diseases. In order to examine the possible increase in the permeability of the blood-brain-barrier (BBB) and resultant infiltration of PBMCs due to cathepsin D (CatD) deficiency, a process underlying the onset of congenital NCL, we examined structural changes in brain vessels in CatD-/- mice. Consequently, the mean diameter of the brain vessels in the cerebral cortex on postnatal day 24 (P24) was significantly larger in CatD-/- mice than in wild type mice. Furthermore, the mean number of brain pericytes in CatD-/- mice began to decline significantly on P16 and almost disappeared by P24, and oxidative DNA damage was first detected in brain pericytes on P12. Examinations with electron microscopy revealed that brain pericytes were laden with dense granular bodies, cytoplasmic vacuoles and lipid droplets. Moreover, pepstatin A, a specific aspartic protease inhibitor, induced mitochondria derived reactive oxygen species (ROS) production in the isolated brain pericytes, which decreased the cell viability. These observations suggest that increased lysosomal storage due to CatD deficiency causes oxidative damage in brain pericytes, subsequently resulting in an increased vessel diameter, enhanced permeability of the BBB and the infiltration of PBMCs.

Recently, much attention has been paid to pericytes as a novel therapeutic target for modifying disease progression in patients with neurodegenerative disorders, such as Alzheimer's disease. In cases of diabetic retinopathy, erythropoietin may also be used as a novel therapeutic agent preventing the drop-out of pericytes from the retinal capillaries. Therefore, the use of agents capable of protecting brain pericytes against oxidative damage may provide the basis for developing alternative therapies for the treatment of neurodegenerative disorders, including NCL and Alzheimer's disease.

zhouw@dent.kyushu-u.ac.jp